title: Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.
abstract: BACKGROUND
  Aplidine is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans.
  
  
  METHODS
  This phase I study of Aplidine given as a 1-hour i.v. infusion daily for 5 days every 3 weeks was conducted in patients with refractory solid tumors. Objectives were to define the dose limiting toxicities, the maximal tolerated dose, and the recommended phase II dose.
  
  
  RESULTS
  Thirty-seven patients were accrued on study. Doses ranged from 80 microg/m(2) to 1500 microg/m(2)/day. Eleven patients received more than three cycles of Aplidine. Dose-limiting toxicities occurred at 1500 microg/m(2) and 1350 microg/m(2)/day and consisted of nausea, vomiting, myalgia, fatigue, skin rash and diarrhea. Mild to moderate muscular pain and weakness was noted in patients treated with multiple cycles with no significant drug related neurotoxicity. Bone marrow toxicity was not observed. The recommended dose for phase II studies was 1200 microg/m(2) daily for 5 days, every 3 weeks. Pharmacokinetic studies performed during the first cycle demonstrated that therapeutic plasma levels of Aplidine are reachable well below the recommended dose. Nine patients with progressive disease at study entry had stable disease and two had minor responses, one in non-small cell lung cancer and one in colorectal cancer.
  
  
  CONCLUSIONS
  Aplidine given at a dose of 1200 microg/m(2) daily for 5 days, every 3 weeks is well tolerated with few severe adverse events. This schedule of Aplidine is under evaluation in phase II studies in hematological malignancies and solid tumors.
authors.affiliation: The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada. jmaroun@ottawahospital.on.ca
authors.forename: J A
authors.initials: JA
authors.lastname: Maroun
authors.forename: K
authors.initials: K
authors.lastname: Belanger
authors.forename: L
authors.initials: L
authors.lastname: Seymour
authors.forename: S
authors.initials: S
authors.lastname: Matthews
authors.forename: J
authors.initials: J
authors.lastname: Roach
authors.forename: J
authors.initials: J
authors.lastname: Dionne
authors.forename: D
authors.initials: D
authors.lastname: Soulieres
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: R
authors.initials: R
authors.lastname: Goel
authors.forename: D
authors.initials: D
authors.lastname: Charpentier
authors.forename: G
authors.initials: G
authors.lastname: Goss
authors.forename: E
authors.initials: E
authors.lastname: Tomiak
authors.forename: J
authors.initials: J
authors.lastname: Yau
authors.forename: J
authors.initials: J
authors.lastname: Jimeno
authors.forename: G
authors.initials: G
authors.lastname: Chiritescu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D002170:Canada; D047630:Depsipeptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D007260:Infusion Pumps; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D010456:Peptides, Cyclic
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D010456:Peptides, Cyclic; C098980:plitidepsin